Prevalence, Predictors And Prognostic Benefits Of Remission Achievement In Patients With Systemic

By analyzing data from 41 studies with 17,270 patients, the prevalence, potential predictors as well as prognostic advantages of remission achievement in patients with systemic lupus erythematosus (SLE) were systematically reviewed and assessed. Despite the lack of consensus on the definition of remission, it was agreed that critical components of defining remission status are: clinical disease activity, serological activity, duration and treatment. The remission status was achieved and maintained for one year in 42.4% to 88% patients, and for at least 5 years in 21.1% to 70%, as per most studies published in the recent 5 years. Older age at diagnosis, lower baseline disease activity and absence of major organ involvement, all were identified as factors related to remission. Overall, in SLE cases, remission represents an achievable and desirable target, and is confirmed to be related to prognostic benefits. In the light of these data, there is a necessity for further development as well as evaluation of a clear remission definition, a risk stratification model and a complete algorithm with frequency of monitoring, timepoints for treatment adjustment and drug withdrawal.

​

Source